Organization (Industry)
OPTOS ApS
ClinicalTrials.gov lists OPTOS ApS as lead sponsor of 18 trials.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 1 registered with a 2026 start date. The dashed outline is the pace from the 1 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 1.8 trial starts a year over the five years to September, under the 5 a year the method needs.
This page covers OPTOS ApS: 18 lead-sponsored trials and 1 legal-entity registration.
Disease areas (16)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Glaucoma | 8 |
| Diabetes Mellitus | 3 |
| Diabetic Retinopathy | 3 |
| Macular Degeneration | 2 |
| Central Serous Chorioretinopathy | 1 |
Showing 5 of 16 disease areas.
Trials by start year as sponsor or collaborator (11)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 1 |
| 2025 | 2 |
| 2024 | 2 |
| 2023 | 1 |
| 2022 | 3 |
| 2021 | 2 |
| 2019 | 6 |
| 2017 | 1 |
| 2016 | 1 |
| 2012 | 2 |
Showing 10 of 11 years.
Recruitment duration, a model prediction: 1 trial still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 43% hit target (n=7) | 14% on time (n=7) |
Journals published in (3)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism | 1 |
| Journal of neurology, neurosurgery, and psychiatry | 1 |
| Multiple sclerosis (Houndmills, Basingstoke, England) | 1 |
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 78 | 41 | 2025-12-02 |
FDA inspection record (1)
| Latest classification | Inspections |
|---|---|
| VAI | 1 |
FDA import refusals (1)
| Refused import lines | Latest refusal |
|---|---|
| 2 | 2023-01-25 |
Manufacturing and distribution sites (1)
| Facility | Location | Regulators | Member organization |
|---|---|---|---|
| OPTOS PLC | DUNFERMLINE, FIFE Fife, GB | FDA |
Organization relationships (1)
| Related organization | Relationship | Evidence |
|---|---|---|
| Genetic Disease Investigators | Co sponsors trial with | 1 |
Latest dated events (107)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-07-29 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2025-12-02 | Patent granted | Granted US patents (PatentsView / USPTO) |
| 2025-10-07 | Patent granted | Granted US patents (PatentsView / USPTO) |
| 2025-08-19 | Patent granted | Granted US patents (PatentsView / USPTO) |
| 2025-08-19 | Patent granted | Granted US patents (PatentsView / USPTO) |
Showing 5 of 107 events.
Biomarker capability evidence (2)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| KCNMA1 | Trial collaborator | Named in trial inclusion criteria |
| KCNMA1 | Trial collaborator | Mentioned in trial text |
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, active development programs, approved assets, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda recalls, climate targets, as filed, workforce and board diversity, as filed, clia clinical laboratory certificates, and biomarkers this organization publishes on.